Novo Nordisk Shows Sickle Cell Efficacy Advantage Over Agios’s Mitapivat

 
• By Alaric DeArment
  
Novo Nordisk announced topline results from the Phase III HIBISCUS trial of etavopivat in sickle cell disease. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Blood and Clotting

More from Disease